

Contents

Foreword (<i>Dr. Paul E. Keck, Jr.</i>)	page vii
Preface: How to Use This Handbook	xi
Introduction	1
1 The Efficacy Story: Acute Mania; Rapid Cycling Bipolar Disorder; Bipolar II Disorder and Bipolar Depression; Bipolar Disorder Prophylaxis, Response Predictors; Unipolar Depression; Suicidality; Aggressive or Impulsive Behavior in Child/Adolescent Patients with Conduct Disorder, in Borderline Personality Disorder or in Patients with Intellectual Disability; Neuroprotective Properties; Elevation of Neutrophil Counts; Mechanisms of Action	24
2 Renal Handling of Lithium: Proximal and Distal Handling of Lithium; The Staging of Chronic Kidney Disease; Lithium Related Effects on Renal Function	95
3 Clinical Pharmacokinetics: Principles Underlying Kinetic and Pharmacodynamic Drug Interactions; Clinically Relevant Drug Interactions and Their Management	151
4 Lithium Initiation and Monitoring: Baseline Assessment; Loading and Initiation Methods; Target Serum Levels; Monitoring Intrinsic Renal Function with New $eGFR_{cr-cys}$ Formula; Office and Laboratory Methods for Monitoring Polyuria; Monitoring Thyroid and Parathyroid Function	203

CONTENTS

- 5 Management of Routine Lithium Related Adverse Effects:** Polyuria, Gastrointestinal Complaints; Altered Taste; Weight Gain; Thyroid and Parathyroid Dysfunction; ECG Changes; Hair Loss; Acneiform Eruptions and Other Skin Disorders; Neutrophilia; CNS Complaints (Tremor, Fatigue, Cognitive and Emotional Dulling, Nystagmus, Myoclonus and Idiopathic Intracranial Hypertension); Peripheral Edema 251
- 6 Lithium Toxicity:** Manifestations and Management of Lithium Toxicity and Overdose; Debate About Hemodialysis Implementation; Safe Use of Lithium During ECT; Clinical Situations When Lithium Should Be Temporarily Discontinued 329
- 7 Special Populations and Circumstances:** Older Bipolar Disorder Patients; Child and Adolescent Bipolar Disorder Patients; Pregnant and Breastfeeding Patients; Lithium Use During Renal Dialysis 362
- 8 Lithium Discontinuation:** Advantages of Gradual Tapering; Suicide Risk Following Discontinuation; Efficacy Upon Resumption 428
- Index* 442